NASDAQ · ONTX
Healthcare · Biotechnology
$16.35
Down-$1.24 (-7.06%)
Updated Aug 25, 2026, 12:51 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
ONTX closed at $16.35 after 21 trading sessions, up 6.76% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $15.745 | $16.77 | $15.44 | $16.3465 | 2.35K |
| Aug 21, 2026 | $17.16 | $17.60 | $16.93 | $17.5884 | 6.27K |
| Aug 20, 2026 | $18.06 | $18.2148 | $17.6801 | $18.2148 | 2.61K |
| Aug 19, 2026 | $19.28 | $19.3268 | $17.56 | $18.48 | 9.82K |
| Aug 18, 2026 | $22.01 | $22.01 | $19.885 | $20.2752 | 7.31K |
| Aug 17, 2026 | $24.65 | $25.99 | $24.65 | $25.73 | 16.8K |
| Aug 14, 2026 | $23.39 | $24.50 | $22.9542 | $22.9542 | 1.93K |
| Aug 13, 2026 | $22.36 | $24.48 | $22.35 | $23.8389 | 4.27K |
| Aug 12, 2026 | $24.10 | $24.30 | $23.39 | $23.60 | 11.72K |
| Aug 11, 2026 | $19.7168 | $21.313 | $19.7168 | $21.313 | 9.67K |
| Aug 10, 2026 | $20.39 | $20.39 | $18.0125 | $18.0125 | 10.23K |
| Aug 7, 2026 | $20.10 | $20.25 | $19.30 | $19.74 | 34.74K |
| Aug 6, 2026 | $16.85 | $17.0699 | $15.52 | $15.80 | 11.83K |
| Aug 5, 2026 | $18.30 | $18.30 | $16.515 | $16.59 | 34.09K |
| Aug 4, 2026 | $17.50 | $18.42 | $17.50 | $18.04 | 2.88K |
| Aug 3, 2026 | $13.73 | $15.7595 | $13.7257 | $15.7595 | 1.37K |
| Jul 31, 2026 | $15.58 | $15.58 | $14.5248 | $14.5248 | 3.53K |
| Jul 30, 2026 | $13.84 | $13.84 | $12.74 | $13.7151 | 2.92K |
| Jul 29, 2026 | $11.36 | $11.37 | $10.62 | $10.62 | 8.17K |
| Jul 28, 2026 | $12.80 | $13.0474 | $12.10 | $13.0474 | 7.09K |
| Jul 27, 2026 | $16.91 | $16.91 | $14.14 | $15.3111 | 4.66K |
The latest Smart Investors Daily articles mentioning ONTX.
ONTX research
Company profile and research snapshot.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 11, 2023 | HC Wainwright & Co. | Buy | — |
| Jun 14, 2023 | HC Wainwright & Co. | Buy | — |
| Jun 6, 2023 | HC Wainwright & Co. | Buy | — |
| May 25, 2023 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Apr 2, 2024
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).
GlobeNewswire Inc. · Mar 8, 2024
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
GlobeNewswire Inc. · Dec 8, 2023
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
GlobeNewswire Inc. · Nov 28, 2023
Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ONTX.
No results
No recent SID articles mention ONTX.
